These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8156964)

  • 61. Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages.
    Steinhoff BJ; Wendling AS
    Epilepsy Res; 2009 Dec; 87(2-3):256-9. PubMed ID: 19850448
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models.
    Fortuna A; Alves G; Soares-da-Silva P; Falcão A
    Epilepsy Res; 2013 Nov; 107(1-2):37-50. PubMed ID: 24050973
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The interaction of denzimol (a new anticonvulsant) with carbamazepine and phenytoin.
    Patsalos PN; Shorvon SD; Elyas AA; Smith G
    J Neurol Neurosurg Psychiatry; 1985 Apr; 48(4):374-7. PubMed ID: 3923158
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Predicting the range of plasma carbamazepine concentrations in patients with epilepsy.
    Racine-Poon A; Dubois JP
    Stat Med; 1989 Nov; 8(11):1327-37. PubMed ID: 2609045
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effect of chronic carbamazepine, valproic acid and phenytoin medication on the periodontal condition of epileptic children and adolescents.
    Galas-Zgorzalewicz B; Borysewicz-Lewicka M; Zgorzalewicz M; Borowicz-Andrzejewska E
    Funct Neurol; 1996; 11(4):187-93. PubMed ID: 8934150
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Carbamazepine-induced systemic lupus erythematosus--a case report].
    Motta E; Kazibutowska Z; Lorek A; Januszewski K; Gołba A; Wianecka A
    Neurol Neurochir Pol; 2006; 40(2):151-5. PubMed ID: 16628512
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
    El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
    J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New injectable aqueous carbamazepine solution through complexing with 2-hydroxypropyl-beta-cyclodextrin: tolerability and pharmacokinetics after intravenous injection in comparison to a glycofurol-based formulation.
    Löscher W; Hönack D; Richter A; Schulz HU; Schürer M; Düsing R; Brewster ME
    Epilepsia; 1995 Mar; 36(3):255-61. PubMed ID: 7614909
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Avoiding neurotoxicity with lithium-carbamazepine combinations.
    McGinness J; Kishimoto A; Hollister LE
    Psychopharmacol Bull; 1990; 26(2):181-4. PubMed ID: 2236454
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cerebellar atrophy decreases the threshold of carbamazepine toxicity in patients with chronic focal epilepsy.
    Specht U; May TW; Rohde M; Wagner V; Schmidt RC; Schütz M; Wolf P
    Arch Neurol; 1997 Apr; 54(4):427-31. PubMed ID: 9109744
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Carbamazepine extended-release capsules use in bipolar disorder: efficacy and safety in adult patients.
    Ginsberg LD
    Ann Clin Psychiatry; 2006; 18 Suppl 1():9-14. PubMed ID: 16754406
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmaceutical and biopharmaceutical quality of a sustained release carbamazepine preparation: a contribution to quality assurance.
    Grunwald F; Czaja J; Düsing R; Schulz HU
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):160-6. PubMed ID: 1592543
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment of benign focal epilepsies in children: when and how should be treated?
    Oguni H
    Brain Dev; 2011 Mar; 33(3):207-12. PubMed ID: 21095081
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects.
    Riva R; Albani F; Ambrosetto G; Contin M; Cortelli P; Perucca E; Baruzzi A
    Epilepsia; 1984 Aug; 25(4):476-81. PubMed ID: 6540170
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Carbamazepine-induced thrombocytopenia.
    Murray GB
    J Clin Psychopharmacol; 1990 Aug; 10(4):305. PubMed ID: 2126793
    [No Abstract]   [Full Text] [Related]  

  • 76. Transient neurologic deficits associated with carbamazepine-induced hypertension.
    Marini AM; Choi JY; Labutta RJ
    Clin Neuropharmacol; 2003; 26(4):174-6. PubMed ID: 12897634
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Carbamazepine extended-release capsules in bipolar disorder.
    Weisler RH
    Neuropsychiatr Dis Treat; 2006 Mar; 2(1):3-11. PubMed ID: 19412441
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Circadian carbamazepine toxicity.
    Haefeli WE; Meyer PG; Lüscher TF
    Epilepsia; 1994; 35(2):400-2. PubMed ID: 8156964
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations.
    Eeg-Olofsson O; Nilsson HL; Tonnby B; Arvidsson J; Grahn PA; Gylje H; Larsson C; Norén L
    J Child Neurol; 1990 Apr; 5(2):159-65. PubMed ID: 2111837
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine.
    Miller AD; Krauss GL; Hamzeh FM
    Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.